VPValeria La Pietra

Valeria La Pietra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Valeria La Pietra has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Self-Assembling Betulinic Acid and Squalene Nanoparticles Enhance the Blood−Brain Barrier Reinforcing Activity of Trehalose

    by Veronica Fontanini, Arianna Amenta, Alice Maiocchi, Barbara Vergani, Biagio Eugenio Leone, Davide Camazzola, Fabrizia Claudia Guarnieri, Luca Murru, Luciana Marinelli, Valeria La Pietra, et al.

    Trehalose, a natural disaccharide with well-established neuroprotective effects in the central nervous system (CNS), has been extensively investigated for its anti-inflammatory, protein-stabilizing, and autophagy-inducing activities. Despite these beneficial CNS effects, its potential impact on the blood−brain barrier (BBB), a key regulator of brain homeostasis and neurological health, remains poorly understood. Here, we demonstrate that trehalose reinforces the in vitro BBB by increasing transendothelial electrical resistance and reducing dextran permeability in hCMEC/D3 monolayers. These functional improvements were associated with AMPK activation and upregulation of the tight junction protein ZO-1, where findings were corroborated in vivo by increased ZO-1 expression in trehalose-treated C57BL/6J mice. Molecular docking further suggested the preferential binding of trehalose to the ZO-1 PDZ3-SH3 domain, supporting a potential mechanism for tight junction stabilization. These findings establish trehalose as a promising BBB-protective agent through complementary molecular mechanisms. Nevertheless, the therapeutic exploitation of free trehalose is hindered by its unfavorable pharmacokinetic properties. To address these limitations and improve its delivery, we engineered four self-assembling trehalose nanoparticles (Treh-NAs) based on mono- or bis-betulinic acid and mono- or bis-squalene conjugates. Nanoparticle encapsulation preserved the barrier-enhancing activity of trehalose while markedly reducing the effective dose in vitro. Among the formulations, the mono-betulinic acid nanoparticles displayed the highest endothelial permeability and the strongest barrier-reinforcing effect. Collectively, these results provide a rationale for the development of trehalose-based nanomedicines aimed at reinforcing the BBB and improving therapeutic interventions for CNS diseases associated with BBB dysfunction, in which the neuroprotective properties of trehalose may provide additional therapeutic benefit.

  • Development and Nanoparticle-Mediated Delivery of Novel MDM2/MDM4 Heterodimer Peptide Inhibitors to Enhance 5-Fluorouracil Nucleolar Stress in Colorectal Cancer Cells

    by Francesco Merlino, Annalisa Pecoraro, Giuseppe Longobardi, Greta Donati, Francesco Saverio Di Leva, Chiara Brignola, Rebecca Piccarducci, Simona Daniele, Claudia Martini, Luciana Marinelli, et al.

    Colorectal cancer (CRC) often involves wild-type p53 inactivation by MDM2 and MDM4 overexpression, promoting tumor progression and resistance to 5-fluoruracil (5-FU). Disrupting the MDM2/4 heterodimer can proficiently reactivate p53, sensitizing cancer cells to 5-FU. Herein, we developed 16 peptides based on Pep3 (1), the only known peptide acting through this mechanism. The new peptides, notably 3 and 9, showed lower IC50 values than 1. When incorporated into tumor-targeted biodegradable nanoparticles, these exhibited cytotoxicity against three different CRC cell lines. Notably, NPs/9 caused a significant increase in p53 levels associated with a strong increment of its main downstream target p21 inducing apoptosis. Also, the combined treatment of 9 with 5-FU caused the activation of nucleolar stress and a synergic apoptotic effect. Hence, the co-delivery of MDM2/4 heterodimer disruptors with 5-FU through nanoparticles might be a promising strategy to overcome drug resistance in CRC.


  • Open Access

    A combined approach of structure‐based virtual screening and NMR to interrupt the PD‐1/PD‐L1 axis: Biphenyl‐benzimidazole containing compounds as novel PD‐L1 inhibitors

    by Greta Donati, Monica Viviano, Vincenzo Maria D'AMore, Alessandra Cipriano, Isidora Diakogiannaki, Jussara Amato, Stefano Tomassi, Diego Brancaccio, Pasquale Russomanno, Francesco Saverio Di Leva, et al.

    Immunotherapy has emerged as a game‐changing approach for cancer treatment. Although monoclonal antibodies (mAbs) targeting the programmed cell death protein 1/programmed cell death protein 1 ligand 1 (PD‐1/PD‐L1) axis have entered the market revolutionizing the treatment landscape of many cancer types, small molecules, although presenting several advantages including the possibility of oral administration and/or reduced costs, struggled to enter in clinical trials, suffering of water insolubility and/or inadequate potency compared with mAbs. Thus, the search for novel scaffolds for both the design of effective small molecules and possible synergistic strategies is an ongoing field of interest. In an attempt to find novel chemotypes, a virtual screening approach was employed, resulting in the identification of new chemical entities with a certain binding capability, the most versatile of which was the benzimidazole‐containing compound 10. Through rational design, a small library of its derivatives was synthesized and evaluated. The homogeneous time‐resolved fluorescence (HTRF) assay revealed that compound 17 shows the most potent inhibitory activity (IC50) in the submicromolar range and notably, differently from the major part of PD‐L1 inhibitors, exhibits satisfactory water solubility properties. These findings highlight the potential of benzimidazole‐based compounds as novel promising candidates for PD‐L1 inhibition.


  • Open Access

    HuR modulation with tanshinone mimics impairs LPS response in murine macrophages

    by Isabelle Bonomo, Giulia Assoni, Valeria La Pietra, Giulia Canarutto, Elisa Facen, Greta Donati, Chiara Zucal, Silvia Genovese, Mariachiara Micaelli, Anna Pérez-Ràfols, et al.

    Lipopolysaccharide exposure to macrophages induces an inflammatory response that is heavily regulated at the transcriptional and post-transcriptional levels. HuR (ELAVL1) is an RNA binding protein that binds and regulates the maturation and half-life of AU/U rich elements (ARE) containing cytokines and chemokines transcripts, mediating the LPS-induced response. Here we investigated how and to what extent small molecule tanshinone mimics (TMs) inhibiting HuR-RNA interaction counteract LPS stimulus in macrophages. We show TMs exist in solution in keto-enolic tautomerism and that, by molecular dynamic calculations, the orto quinone form is the bioactive species interacting with HuR and inhibiting its binding mode vs mRNA targets. A chemical blockage of the diphenolic, reduced form as a diacetate caused the loss of activity of TMs in vitro but resulted to prodrug-like activity in vivo . The murine macrophage cell line RAW264.7 was treated with LPS and TMs, and the modulation of cellular LPS-induced response was monitored by RNA and Ribonucleoprotein immunoprecipitation sequencing. Correlation analyses indicated that LPS induced a strong coupling between differentially expressed genes and HuR-bound genes, and that TMs reduced such interactions. Functional annotation addressed a specific set of genes involved in chemotaxis and immune response, such as Cxcl10, Il1b, Cd40 , and Fas , with a decreased association with HuR, a reduction of their expression and protein secretion. The same effect was observed in primary murine bone marrow-derived macrophages, and in vivo in an LPS induced peritonitis model, in which the serum level of Cxcl10 and Il1b was strongly reduced, endowing TMs such as TM7nox with remarkable anti-inflammatory properties in vivo .


  • Open Access

    Identification of a Novel p53 Modulator Endowed with Antitumoural and Antibacterial Activity through a Scaffold Repurposing Approach

    by Elisa Nuti, Valeria La Pietra, Simona Daniele, Doretta Cuffaro, Lidia Ciccone, Chiara Giacomelli, Carolina Cason, Alfonso Carotenuto, Vincenzo Maria D’amore, Eleonora Da Pozzo, et al.

    Intracellular pathogens, such as Chlamydia trachomatis, have been recently shown to induce degradation of p53 during infection, thus impairing the protective response of the host cells. Therefore, p53 reactivation by disruption of the p53–MDM2 complex could reduce infection and restore pro-apoptotic effect of p53. Here, we report the identification of a novel MDM2 inhibitor with potential antitumoural and antibacterial activity able to reactivate p53. A virtual screening was performed on an in-house chemical library, previously synthesised for other targets, and led to the identification of a hit compound with a benzo[a]dihydrocarbazole structure, RM37. This compound induced p53 up-regulation in U343MG glioblastoma cells by blocking MDM2–p53 interaction and reduced tumour cell growth. NMR studies confirmed its ability to dissociate the MDM2–p53 complex. Notably, RM37 reduced Chlamydia infection in HeLa cells in a concentration-dependent manner and ameliorated the inflammatory status associated with infection.


  • Open Access

    Enriching the Arsenal of Pharmacological Tools against MICAL2

    by Ivana Barravecchia, Elisabetta Barresi, Camilla Russo, Francesca Scebba, Chiara De Cesari, Valerio Mignucci, Davide De Luca, Silvia Salerno, Valeria La Pietra, Mariateresa Giustiniano, et al.

    Molecule interacting with CasL 2 (MICAL2), a cytoskeleton dynamics regulator, are strongly expressed in several human cancer types, especially at the invasive front, in metastasizing cancer cells and in the neo-angiogenic vasculature. Although a plethora of data exist and stress a growing relevance of MICAL2 to human cancer, it is worth noting that only one small-molecule inhibitor, named CCG-1423 (1), is known to date. Herein, with the aim to develop novel MICAL2 inhibitors, starting from CCG-1423 (1), a small library of new compounds was synthetized and biologically evaluated on human dermal microvascular endothelial cells (HMEC-1) and on renal cell adenocarcinoma (786-O) cells. Among the novel compounds, 10 and 7 gave interesting results in terms of reduction in cell proliferation and/or motility, whereas no effects were observed in MICAL2-knocked down cells. Aside from the interesting biological activities, this work provides the first structure–activity relationships (SARs) of CCG-1423 (1), thus providing precious information for the discovery of new MICAL2 inhibitors.


  • CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme

    by Simona Daniele, Valeria La Pietra, Rebecca Piccarducci, Deborah Pietrobono, Chiara Cavallini, Vincenzo Maria D'AMore, Linda Cerofolini, Stefano Giuntini, Pasquale Russomanno, Michela Puxeddu, et al.


  • Computer-Aided Identification and Lead Optimization of Dual Murine Double Minute 2 and 4 Binders: Structure–Activity Relationship Studies and Pharmacological Activity

    by Mariateresa Giustiniano, Simona Daniele, Sveva Pelliccia, Valeria La Pietra, Deborah Pietrobono, Diego Brancaccio, Sandro Cosconati, Anna Messere, Stefano Giuntini, Linda Cerofolini, et al.

    The function of p53 protein, also known as “genome guardian”, might be impaired by the overexpression of its primary cellular inhibitor, the murine double minute 2 protein (MDM2). However, the recent finding that MDM2-selective inhibitors induce high levels of its homologue MDM4, prompt us to identify, through a receptor-based virtual screening on an in house database, dual MDM2/MDM4 binders. Compound 1 turned out to possess an IC50 of 93.7 and of 4.6 nM on MDM2 and MDM4, respectively. A series of compounds were synthesized to optimize its activity on MDM2. As a result, compound 12 showed low nanomolar IC50 for both targets. NMR studies confirmed the pocket of binding of 12 as predicted by the Glide docking software. Notably, 12 was able to cause concentration-dependent inhibition of cell proliferation, yielding an IC50 value of 356 ± 21 nM in neuroblastoma SHSY5Y cells and proved even to efficiently block cancer stem cell growth.